| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0022-5347(05)66597-4 |
| P698 | PubMed publication ID | 11176535 |
| P2093 | author name string | Nakajima M | |
| Gohji K | |||
| Kitazawa S | |||
| Katsuoka Y | |||
| Tamada H | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1033-1036 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Expression of endothelin receptor a associated with prostate cancer progression | |
| P478 | volume | 165 |
| Q48456368 | A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer |
| Q36801764 | Bone metabolism and new targets for intervention |
| Q28476183 | Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells |
| Q47893128 | Clinical trials of atrasentan in hormone-refractory prostate cancer. |
| Q58090688 | Clinicopathological Significance of the ET Axis in Human Oral Squamous Cell Carcinoma |
| Q38009942 | Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer |
| Q80682648 | Distinct patterns of endothelin axis expression in primary prostate cancer |
| Q35581005 | Endothelin Inhibition: Novel Therapy for Prostate Cancer |
| Q38273539 | Endothelin receptor A blockade enhances taxane effects in prostate cancer |
| Q36011743 | Endothelin receptor antagonists |
| Q82683852 | Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics |
| Q35074833 | Endothelin-1: a multifunctional molecule in cancer |
| Q80295691 | Endothelin-a receptor antagonists and advanced prostate cancer |
| Q38413647 | Endothelin‐1: a predictor of extracapsular extension in clinically localized prostate cancer? |
| Q41847322 | Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy |
| Q26865532 | From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors |
| Q35634255 | G proteins in cancer: the prostate cancer paradigm |
| Q50764397 | Highlights from the 41st Annual Meeting of the American Society of Clinical Oncology, May 2005, and the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, February 2005, Orlando, Florida. |
| Q41056011 | Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel. |
| Q40118054 | Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line |
| Q35579300 | Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease |
| Q37958741 | Novel options for the treatment of castration-resistant prostate cancer |
| Q33642278 | Novel targeted therapeutics for metastatic castration-resistant prostate cancer. |
| Q43257053 | Palliative systemic therapy of castration-resistant prostate cancer: current developments |
| Q34898980 | Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer |
| Q37380585 | Prostate cancer epigenetics: a review on gene regulation. |
| Q60156303 | Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer |
| Q82437098 | Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells |
| Q41807720 | Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells |
| Q39664054 | Role of p115RhoGEF in the regulation of extracellular Ca2+‐induced choline kinase activation and prostate cancer cell proliferation |
| Q96304042 | Sleeve gastrectomy ameliorates endothelial function and prevents lung cancer by normalizing endothelin-1 axis in obese and diabetic rats |
| Q37971873 | Targeting the endothelin axis in prostate carcinoma |
| Q28206793 | The endothelin axis: emerging role in cancer |
| Q37153468 | The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways |
| Q45454130 | The role of the endothelin axis in promoting epithelial to mesenchymal transition and lymph node metastasis in prostate adenocarcinoma |
| Q36956936 | Tumor-evoked sensitization of C nociceptors: a role for endothelin |
| Q81615621 | ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer |
Search more.